Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

@article{Hodi2016CombinedNA,
  title={Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.},
  author={Frank Stephen Hodi and Jason A Chesney and Anna C Pavlick and Caroline Robert and Kenneth F. Grossmann and D F Mcdermott and Gerald P. Linette and N Meyer and Jeffrey K. Giguere and Sanjiv S. Agarwala and Montaser F. Shaheen and Marc S. Ernstoff and David R. Minor and April K. S. Salama and Matthew Hiram Taylor and Patrick Alexander Ott and Christine E. Horak and Paul Gagnier and Joel Jiang and Jedd D Wolchok and Michael A Postow},
  journal={The Lancet. Oncology},
  year={2016},
  volume={17 11},
  pages={1558-1568}
}
BACKGROUND Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 132 extracted citations

Similar Papers

Loading similar papers…